DNA Script is the world’s leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims at accelerating innovation in life sciences and technology through rapid, affordable, and high-quality DNA synthesis. DNA Script’s approach leverages nature's billions of years of evolution in synthesizing DNA to enable genome scale synthesis.

The Company’s technology has the potential to greatly accelerate the development of new therapeutics, sustainable chemicals production, improved crops as well as data storage.


Team Member
more about
Arnaud Autret
Investment Director
Latest News Entry
DNA Script Obtains CE Mark for SYNTAX DNA Printing Platform

DNA Script, a leader in Enzymatic DNA Synthesis (EDS), announced the CE marking of its SYNTAX System, the first EDS-powered benchtop DNA printer

DNA Script Raises $165M in Oversubscribed Series C Financing to Accelerate Commercialization of Enzymatic DNA Printing Platform

New Funding, Targeted to Accelerate Application Expansion and Platform Commercialization, Brings Total Amount Raised to Date to $280M

DNA Script Expands Series B to $89M

Casdin Capital leads the $50M extension; funding will support commercial launch of SYNTAX™️ — the world’s first enzymatic DNA printer.

DNA Script Raises $38.5 Million in Series B Financing

Oversubscribed round led by LSP will fund accelerated product development and commercial operations in the U.S.

M Ventures participates in DNA Script' Successful Series A Fundraising of €11 M to Advance Development of its DNA Synthesis Technology

Paris, September 12th, 2017. Synthetic DNA manufacturer DNA Script has today announced a Series A fundraising of 11 million euros ($13 million) led by Illumina Ventures, with additional investments from M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany, plus existing investors Sofinnova Partners, Kurma Partners, and Idinvest Partners.

all related news
all portfolio news